Novo's next-gen obesity drug shows positive results, heads to late-stage testing ⊕
Novo Nordisk said its experimental drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Novo
since
auto-detected in 95 stories
11 days ago
12 days ago
Weight loss jabs do not slow Alzheimer's disease as hoped, causing firm's share prices to plummet ⊕
found
a story from The Daily Mail 💩 › The Daily Mail
Novo Nordisk had hoped to repurpose semaglutide - the active ingredient in its Wegovy and Ozempic jabs - as a groundbreaking dementia treatment after seeing early encouraging signs.
Novo Nordisk stumbles against Eli Lilly in GLP-1 drug battle. Which stock is the best buy from here? ⊕
found
Eli Lilly's stock is soaring while Novo Nordisk is sinking. Why it makes sense to stick with the market winner, despite its rising valuation.
Novo Nordisk shares plunge 10% after Alzheimer's drug trial fails to hit key target ⊖
Shares of Novo Nordisk plunged after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer's disease failed to meet its main goal.
Novo Nordisk shares slump after drug failure in Alzheimer’s trial
found
a story from Financial Times ✅ › Financial Times
Outcome is blow to one of Europe’s largest listed companies
19 days ago
Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
found
The announcements come days after President Donald Trump struck deals with Novo Nordisk and Eli Lilly to make their GLP-1s easier for Americans to access.
22 days ago
Novo Nordisk's leadership strategy tested as shareholders signal frustration ahead of vote on board revamp
Novo Nordisk has found itself in an increasingly chaotic situation as of late, with shares plunging and investor confidence waning.
24 days ago
Healthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill with additional data ⊕
Novo Nordisk released new data to underscore its pill's safety and effectiveness, while Trump is asked whether private plans could see lower GLP-1 costs.
25 days ago
Novo Nordisk walked away from a $10 billion biotech deal — and investors aren’t sure if that’s smart or scary
A failed acquisition bid, U.S. pricing deals, and boardroom drama pose challenges for the Danish pharma giant.
30 days ago
Novo Nordisk again raises bid in battle for obesity start-up Metsera
found
a story from Financial Times ✅ › Financial Times
Danish company vies with Pfizer for control of US biotech as they seek edge in growing market for weight-loss drugs